EN DE
Watch Airsculpt Technologies Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Airsculpt Technologies Inc (AIRS) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Airsculpt Technologies Inc stock $0.43, price $0.53, that is 20.4% below the price, quality 27 out of 100. Rating: overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AT Airsculpt Technologies Inc logo Thin data Nov 7, 2026

Airsculpt Technologies Inc

AIRS · US
Expensive, weak quality

Our calculation puts a fair price 20% below what the stock costs today.

Moderate debt
Fair value $0.4250 · Overvalued
Quality 27/100
Weak Growth (revenue 3y −3.5 %/yr in USD)
Loss-making · -7.8% net margin (TTM)
Negative free cash flow over the last twelve months
Trails peers (1/11)
Narrow moat 13/100 · thin data
Thin data
⚠ Dilution
Watch Airsculpt Technologies Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$17.24 $0.5340 Fair Value $0.4250 Oct 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $0.5340 – $17.24 · fair‑value band $0.1020 – $0.7565 · the $0.5340 price screens above the $0.4250 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Airsculpt Technologies in your weekly email

Every Wednesday you see whether Airsculpt Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada.

Show moreShow less

The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure.

It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool.

In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient's own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas.

Further, the company's body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers.

The company was founded in 2012 and is headquartered in Miami Beach, Florida.

Stock analysis

Airsculpt Technologies Inc (AIRS) currently trades at $0.5340, while our model-based Fair Value estimate is $0.4250, 20% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $0.5000 per share, and 1 of the 5 models we run sit above the $0.5340 price.

Bear case: the Growth DCF group reads lowest at $0.2400, and 4 of the 5 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.1020 (bear) to $0.7565 (bull), the price of $0.5340 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Airsculpt Technologies Inc reported revenue of $152M in FY2025 versus $133M in FY2021, a compound +3.3%/yr. Reported net income was −$11.7M in FY2025.

Key figures

Market cap $37.8M Micro · P/S ratio 0.26 · EPS (TTM) $−0.1200 · Net margin −7.7% · Return on equity −12.0% · Return on assets (EBIT) 1.4% (5-year average) · Operating margin −0.1% · Revenue (TTM) $151M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).

What moves the price

The share trades about 95% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −20%, AIRS screens richer than that median.

Fair Value models

Bear $0.1020 Fair Value $0.4250 Bull $0.7565
Price $0.5340 · Downside -20.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $0.0400 $0.2500 $0.5100 70
Growth DCF $0.0500 $0.2400 $0.4500 70
5Y EBITDA Exit $0.2600 $0.7400 $1.29 69
All 6 models by family
DCF Models
FCF DCF $0.0400 $0.2500 $0.5100 70
5Y EBITDA Exit $0.2600 $0.7400 $1.29 69
10Y Revenue Exit n/a n/a $0.0300 62
10Y EBITDA Exit $0.1500 $0.5000 $0.9500 61
Multiples
EV/EBITDA $0.1200 $0.5000 $0.8900 60
Growth DCF
Growth DCF $0.0500 $0.2400 $0.4500 70

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 29
How much profit the company makes from its sales and capital
Quality Growth 19
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 38
Debt, balance sheet and risk of trouble
Investment 88
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 1
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 1
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyJorey Chernett10% owner12× since Mar 3, 2026: 810,150 shares, avg. $2.45$2.0MApr 17, 2026

Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−15.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.0% (2020) → −3.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+53.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.9%
Yearly sales growth analysts expect, extended to five years.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +50.0% a year for the price and −0.5% for the forecasts.
Forecast 2026 (sales)−0.5%
Forecast 2027 (sales)+2.7%
Projected 2028 (sales)+2.6%
Projected 2029 (sales)+2.5%
Projected 2030 (sales)+2.4%

AIRS screens overvalued: fair value 20% below the price. Compare with HCA Healthcare, Inc →

Compare Airsculpt Technologies Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks

Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −20.4% · Below median
Profitability
Return on assets −6.2% · Bottom 25%
Net margin (12 months) −7.8% · Bottom 25%
Operating margin (12 months) −0.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −2.5% · Bottom 25%
Balance sheet
Debt / equity 0.58× · Highest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 0.43× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.25× · Cheapest 25%
Price / free cash flow (fiscal year) 54.6× · Priciest 25%
EV/EBITDA 12.7× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)6 · sector 34
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 32
HEALTH (low debt)71 · sector 90
DIVIDEND (yield)0 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $23.40 $46.55 +99% vs AIRS
Aier Eye Hospital Group 300015 ¥9.01 ¥10.88 +21% vs AIRS
DaVita Inc DVA $191.35 $218.90 +14% vs AIRS
HCA Healthcare, Inc HCA $494.99 $547.34 +11% vs AIRS
Tenet Healthcare Corporation THC $283.33 $279.20 −1% vs AIRS
The Ensign Group ENSG $181.08 $140.09 −23% vs AIRS
Encompass Health Corporation EHC $137.54 $94.81 −31% vs AIRS
Fresenius SE FRE €52.48 €34.77 −34% vs AIRS
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,446 ₹5,234 −38% vs AIRS
Dr. Sulaiman Al Habib Medical Services Group 4013 215.00 SAR 109.45 SAR −49% vs AIRS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Airsculpt Technologies Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Airsculpt Technologies Inc Fair Value". https://www.fairvalue-calculator.com/stock/AIRS

Frequently asked questions

Is Airsculpt Technologies Inc (AIRS) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $0.4250 versus a price of $0.5340, about 20% lower (overvalued).
What is the fair value of AIRS?
Our model-based fair value for Airsculpt Technologies Inc is $0.4250 (as of Nov 7, 2026), built from audited fundamentals. The current price: $0.5340.
What is the quality score of AIRS?
Airsculpt Technologies Inc has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Airsculpt Technologies Inc (AIRS)?
Our model-based price target is the fair value of $0.4250 (as of Nov 7, 2026) from 6 valuation models. Cautious scenario $0.1020, optimistic scenario $0.7565. It is a calculation from audited fundamentals, not an analyst target.
What is the Airsculpt Technologies Inc stock forecast for 2026?
Our models put fair value at $0.4250, about 20% lower versus a price of $0.5340 (overvalued). Cautious scenario $0.1020, optimistic scenario $0.7565. The calculation is refreshed regularly with new filings.
What is the revenue of Airsculpt Technologies Inc (AIRS)?
Airsculpt Technologies Inc reported trailing-twelve-month revenue of about $151M (latest available figure, as of Nov 7, 2026).
What growth is priced into Airsculpt Technologies Inc (AIRS)?
For today's price to be fair in a discounted-cash-flow model, Airsculpt Technologies Inc would have to grow free cash flow by +53.5 % per year for five years (discount rate 12.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.3 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of AIRS use?
Our models discount Airsculpt Technologies Inc at 12.2 %: a base by market capitalisation (nano), damped by beta 2.28, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Airsculpt Technologies Inc that is +53.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.2 %) and the same formula as our fair value.
How much growth has Airsculpt Technologies Inc (AIRS) delivered so far?
Over the past 5 years revenue at Airsculpt Technologies Inc grew +19.3 % a year. The price currently implies free-cash-flow growth of +53.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Airsculpt Technologies Inc (AIRS) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Airsculpt Technologies Inc (+53.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Airsculpt Technologies Inc (AIRS)?
The free-cash-flow yield on the price is 1.83 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Airsculpt Technologies Inc produces per unit of market value. When it exceeds the discount rate of our models (12.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Airsculpt Technologies Inc (AIRS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Airsculpt Technologies Inc it is $0.4250 per share (as of Nov 7, 2026), against a price of $0.5340. It is the blended result of 6 valuation models in 3 families (DCF Models, Multiples, Growth DCF).
Is Airsculpt Technologies Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, AIRS trades above its calculated fair value: price $0.5340, fair value $0.4250, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AIRS?
No. The price is what the market pays today ($0.5340); the fair value is what the company's own numbers justify ($0.4250). For Airsculpt Technologies Inc the two are $0.1090 per share apart. That gap is exactly why we show both numbers side by side.
How much is Airsculpt Technologies Inc worth?
The market values Airsculpt Technologies Inc at about $37.8M (market capitalisation, as of Nov 7, 2026). Per share that is $0.5340; our models calculate a fair value of $0.4250 per share.
What do the bullish and bearish scenarios say about AIRS?
Our models span a range for Airsculpt Technologies Inc: cautious scenario $0.1020, base $0.4250, optimistic $0.7565 per share (as of Nov 7, 2026, price $0.5340). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Airsculpt Technologies Inc (AIRS)?
Balance-sheet figures for Airsculpt Technologies Inc (as of Nov 7, 2026): return on equity −12.0%, debt of 0.58 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is AIRS from its 52-week high?
Airsculpt Technologies Inc trades at $0.5340, about 95% below its 52-week high of $10.49 and at the low of $0.5340 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4250 is for.
Which stocks are comparable to Airsculpt Technologies Inc?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Airsculpt Technologies Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $0.5340, calculated fair value $0.4250 (−20%), Quality Score 27/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AIRS calculated?
We run Airsculpt Technologies Inc through 6 models from 3 families: DCF Models, Multiples, Growth DCF. Every model gets the same audited fundamentals; the fair value of $0.4250 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Airsculpt Technologies Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Airsculpt Technologies Inc (AIRS)?
The closing price on Nov 6, 2026 was $0.5340. Our model-based fair value is $0.4250, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Airsculpt Technologies Inc right now?
Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($0.1020 to $0.7565). The outcome hinges heavily on assumptions, so read the point estimate with caution. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Airsculpt Technologies Inc

How large is the market capitalisation of Airsculpt Technologies Inc (AIRS)?
The market capitalisation of Airsculpt Technologies Inc is $37.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Airsculpt Technologies Inc (AIRS)?
The price-to-sales ratio of Airsculpt Technologies Inc is 0.26 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Airsculpt Technologies Inc (AIRS)?
Earnings per share at Airsculpt Technologies Inc are $−0.1200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Airsculpt Technologies Inc (AIRS)?
The net margin of Airsculpt Technologies Inc is −7.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Airsculpt Technologies Inc (AIRS)?
The return on equity (ROE) of Airsculpt Technologies Inc is −12.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Airsculpt Technologies Inc (AIRS)?
On an EBIT basis the return on assets of Airsculpt Technologies Inc is 1.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Airsculpt Technologies Inc (AIRS)?
The operating margin of Airsculpt Technologies Inc is −0.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Airsculpt Technologies Inc (AIRS)?
Revenue at Airsculpt Technologies Inc is growing −2.5% versus a year earlier (3y avg −3.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Airsculpt Technologies Inc (AIRS)?
Earnings per share at Airsculpt Technologies Inc are growing +200% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Airsculpt Technologies Inc (AIRS) carry?
The net debt of Airsculpt Technologies Inc is $75.1M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Airsculpt Technologies Inc in the live analysis

One click puts Airsculpt Technologies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.